Immix Biopharma, Inc. IMMX
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Immix Biopharma, Inc. (IMMX) is a healthcare company listed in the US with a market value of about $657M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -57%.
About Immix Biopharma
Immix Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 137% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$29M | -$22M | -$15M | -$8M | -$24M | -$1M |
| Free cash flow | -$25M | -$16M | -$11M | — | -$2M | — |
| EPS (diluted) | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-6.64 | $-0.34 |
| Net margin | — | — | — | — | — | — |
| ROIC | -24.9% | -125.0% | -77.7% | -49.3% | -5.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $23.80, 204% above the current price; targets range from $17.40 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-0.73 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Immix Biopharma pay a dividend?
Not currently.
Is Immix Biopharma a good stock to buy?
We do not give buy or sell advice. Immix Biopharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.